Impact Analysis of Covid-19 The complete version of the Report will include the impact of the COVID-19, and anticipated change on the future outlook of the industry, by taking into the account the political, economic, social, and technological parameters. Request Sample

Erectile Dysfunction: A Prominent Age Related Disorder

Erectile dysfunction (ED) is the recurrent inability to reach or to maintain a penile erection sufficient during sexual activities. It is one of the most common male sexual health disorder. It affects physical and psychosocial health and significantly impacts on the sexual life of patients and their partners. The main symptom of the condition is the inability to attain or maintain firm erection during sexual intercourse. Erectile dysfunction can be classified in two types psychogenic and organic.

The global erectile dysfunction treatment market was valued at US$ 4,946.2 million in 2018, and is expected to exhibit a CAGR of 6.2% over the forecast period (2019 – 2027).

Figure 1. Global Erectile Dysfunction Treatment Market Share (%), By Product Type, 2019 and 2027

Source: Coherent Market Insights Analysis (2019)

Manufacturers are focused on production of generic versions of drugs, owing to expiry of drug patents

Expiry of drug patents have led companies to focus on manufacturing generic versions of drugs for erectile dysfunction. For instance, Eli Lilly’s drug, Cialis, lost patent protection in September 2018. In October 2018, Teva Pharmaceutical launched a generic version of Cialis in the U.S., which is used for treatment of erectile dysfunction. Moreover, in March 2019, Dr. Reddy's Laboratories launched a generic version of Cialis (Tadalafil) tablets, in the U.S. market. Furthermore, in December 2017, Pfizer Inc. launched a generic version of Viagra, Sildenafil Citrate, for treatment of erectile dysfunction. Furthermore, in November, 2018, Alembic Pharmaceuticals launched an AB-rated generic version of Bayer’s Staxyn (vardenafil) orally disintegrating tablet for the treatment of ED.

Adoption of inorganic strategies by key players is expected to propel the global erectile dysfunction treatment market growth over the forecast period

Key players are focused on expansion of their erectile dysfunction product portfolio through various strategies such as collaborations, merger and acquisitions. For instance, in July 2019, Pfizer Inc., merged with Mylan for its off-patent drugs division (Upjohn), which includes Viagra (an erectile dysfunction drug), and Lipitor (a cholesterol treating drug).

Increasing prevalence of erectile dysfunction is expected to drive the global erectile dysfunction treatment market growth

Erectile dysfunction is a condition related to age and secondary medical conditions such as diabetes, hypertension, dyslipidemia, depression, and cardiovascular disease. For instance, in 2015, a study was conducted by the Canadian Institute of Health Research on 4,000 Canadian men aged between 40 to 88 years. The result of the study showcased that out of 4,000 Canadian men, 50% of them suffered with erectile dysfunction. ED is more prevalent in men with cardiovascular disease, and diabetes. Such increasing prevalence of erectile dysfunction is expected to increase demand for the drugs used in ED treatment, which is expected to drive the global erectile dysfunction treatment market growth over the forecast period.

Global Erectile dysfunction market – Regional Insights

Based on region, the global erectile dysfunction treatment market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.

Among regions, North America is expected to hold a dominant position in global erectile dysfunction treatment market over the forecast period, owing to increasing prevalence of erectile dysfunction and presence of key players in North America region. For instance, in June 2018, according to the Cleveland Clinic Foundation, 617,715 people reported to have erectile dysfunction in the U.S. and this is expected to increase the demand of drugs used for ED treatment, which is expected to drive the global erectile dysfunction treatment market growth. Moreover, key players such as Pfizer Inc, Eli Lilly and Company, and others are present in North America region, these manufacturers are engaged in manufacturing products for ED treatment, which is expected to boost the global erectile dysfunction treatment market growth.

Europe is also expected to witness a significant growth over the forecast period, owing to increasing prevalence of erectile dysfunction. For instance, according to the NCBI, in March 2019, overall prevalence of erectile dysfunction in Germany was 25.2% (among which 3.1% was severe, 9.2% was moderate, 8.7% was mild, and 4.2% was mild to moderate). These factors are expected to drive global erectile dysfunction treatment market growth over the forecast period.

Figure 2: Global Erectile Dysfunction Treatment Market Share (%), By Region, (2019 & 2027)

Source: Coherent Market Insights Analysis (2019)

Restraints

Factors restraining the global erectile dysfunction treatment market are the availability of the alternative treatments such as natural remedies, herbal Viagra, devices used for treating ED, surgical replacements, and others.

Key Players

Key players operating in the global erectile dysfunction treatment market include Mylan Pharmaceuticals Inc, Cipla Ltd, Aurobindo Pharma Ltd, Eli Lily & Co, Novartis International AG, Torrent Pharmaceuticals Ltd, Pfizer Inc, Bayer Pharma AG, Dr. Reddys Laboratories Ltd, and Dong-A Pharmaceutical Co., Ltd.